Clinical Findings

GLP-1 drugs cut heart events, deaths, and heart-failure hospital stays in large trials — not just weight

Obesity is a rapidly growing global health problem, strongly linked to cardiovascular disease and death, and the standard responses leave many people unprotected. Lifestyle change remains the cornerstone of treatment, but average long-term weight loss is modest and durable weight maintenance is often limited; weight-loss surgery is not suitable for every patient, and substantial weight regain occurs in a considerable proportion of people over time. GLP-1 receptor agonists, medicines first developed for type 2 diabetes, have emerged as potent tools for weight reduction and cardiometabolic risk improvement. Across the large cardiovascular-outcome trials, they consistently reduce major adverse cardiovascular events, deaths from any cause, and heart-failure hospitalizations in people with type 2 diabetes. The benefit is not confined to diabetes: in people with overweight or obesity who do not have diabetes, semaglutide, in the SELECT trial, significantly reduced cardiovascular risk — and that protection was partly independent of how much weight was lost.